Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials
Whether or whether or not tirofiban is beneficial within side the quick time period for sufferers with STEMI who go through PCI is debatable. A meta-analysis validated the short-term efficacy and safety of tirofiban in patients with ST-phase elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Comparing STEMI patients undergoing PCI with and without tirofiban. We found all relevant randomised controlled trials by searching scientific databases and websites. This fixed-results model computed RR and 95% CI. 10 RCTs included 5008 people. After 30 days, death from any cause (RR 0.79, CI 0.55-1.12, P=0.18), major bleeding (1.37, 0.93-2.03, P=0.11), or transfusion (1.23, 0.94-1.61, P=0.13) were no longer impacted. Minor bleeding (1.29, 1.02-1.63, P=0.04), thrombocytopenia (2.04, 1.40-2.97, P=0.0002), and 6-month all-purpose mortality (0.57, 0.36-0.90, P=0.02) showed statistically significant differences. Repeat revascularization (0.58, 0.43-0.78, P=0.0004) and myocardial infarction (0.55, 0.33-0.92, P=0.02) also differed. Mild bleeding and thrombocytopenia are more common with tirofiban, although reinfarction, revascularization, and death after 6 months are decreased.
-
Tirofiban, Percutaneous Coronary Intervention, ST-Segment Elevation, My0cardial Infarction
-
(1) Zia ur Rahman
MBBS, FCPS, Department of Cardiology, Hayatabad Medical Complex, Peshawar, KP, Pakistan.
(2) Irfan Ali Khan
MBBS, FCPS, Department of Cardiology, Hayatabad Medical Complex, Peshawar, KP, Pakistan.
(3) Qazi Najeeb Ullah Amin
MBBS, FCPS, Department of Cardiology, Hayatabad Medical Complex, Peshawar, KP, Pakistan.
(4) Kashif Ullah
MBBS, FCPS, Department of Cardiology, Hayatabad Medical Complex, Peshawar, KP, Pakistan.
(5) Farman Ullah
MBBS, FCPS, Department of Cardiology, Hayatabad Medical Complex, Peshawar, KP, Pakistan.
(6) Sami Ullah
MBBS, FCPS, Department of Cardiology, Hayatabad Medical Complex, Peshawar, KP, Pakistan.
- Alkhatib, A., Sunoqrot, M., Hussien, A., Sayed, A., & Abdelhakim, A. (2022). Efficacy of Intracoronary versus Intravenous Abciximab in Cardiac Inflammatory Markers and Cardiac Function in Myocardial Infarctionn Patients. Authorea Preprints.
- Allencherril, J., Alam, M., Levine, G., Jneid, H., Atar, D., Kloner, R. A., & Birnbaum, Y. (2018). Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction? Journal of Cardiovascular Pharmacology and Therapeutics, 24(3), 215–224. https://doi.org/10.1177/1074248418812167
- Badescu, M. C., Ciocoiu, M., Rezus, E., Badulescu, O. V., Tanase, D. M., Ouatu, A., Dima, N., Ganceanu-Rusu, A. R., Popescu, D., Seritean Isac, P. N., Genes, T. M., & Rezus, C. (2021). Current Therapeutic Approach to Acute Myocardial Infarction in Patients with Congenital Hemophilia. Life, 11(10), 1072. https://doi.org/10.3390/life11101072
- Bai, N., Niu, Y., Ma, Y., Shang, Y. S., Zhong, P. Y., & Wang, Z. L. (2022). Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials. Journal of Interventional Cardiology, 2022.
- Bentur, O. S., Li, J., Jiang, C. S., Martin, L. H., Kereiakes, D. J., & Coller, B. S. (2021). Application of Auxiliary VerifyNow Point- of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist. TH Open, 05(03), e449–e460. https://doi.org/10.1055/s-0041-1732343
- Des Kölner Infarkt Modells, K. I. M., & Streller, L. A. (n.d). Aus dem Zentrum fü r Innere Medizin der Universitä t zu Kö ln Klinik und Poliklinik fü r Innere Medizin III Kardiologie Direktor: Universitä tsprofessor Dr. med. St. Baldus.
- Fagel, N. D. (2022). Invasive strategies in patients with acute coronary syndrome.
- Jakubiak, G. K., Pawlas, N., Cieślar, G., & Stanek, A. (2021b). Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes. International Journal of Environmental Research and Public Health, 18(22), 11970. https://doi.org/10.3390/ijerph182211970
- James, S., Koul, S., Andersson, J., Angerås, O., Bhiladvala, P., Calais, F., Danielewicz, M., Fröbert, O., Grimfjärd, P., Götberg, M., Henareh, L., Ioanes, D., Jensen, J., Linder, R., Lindroos, P., Omerovic, E., Panayi, G., Råmunddal, T., Sarno, G., . . . Erlinge, D. (2021). Bivalirudin Versus Heparin Monotherapy in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 14(12). https://doi.org/10.1161/circinterventions.120.008969
- Karathanos, A., Lin, Y., Dannenberg, L., Parco, C., Schulze, V., Brockmeyer, M., & Wolff, G. (2019). Routine glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta- analysis. Canadian Journal of Cardiology, 35(11), 1576-1588.
- Kingma, J. G. (2018). Myocardial Infarction: An Overview of STEMI and NSTEMI Physiopathology and Treatment. World Journal of Cardiovascular Diseases, 08(11), 498–517. https://doi.org/10.4236/wjcd.2018.811049
- Onishi, A., Omae, K., Luo, Y., Imai, H., Takahashi, S., Itaya, T., Pinson, C., Nevitt, S. J., & Furukawa, T. A. (2020). No consistent evidence of data availability bias existed in recent individual participant data meta- analyses: a meta-epidemiological study. Journal of Clinical Epidemiology, 118, 107- 114.e5. https://doi.org/10.1016/j.jclinepi.2019.10.004
- Perivoliotis, K., Sioka, E., Katsogridaki, G., & Zacharoulis, D. (2018a). Laparoscopic Gastric Plication versus Laparoscopic Sleeve Gastrectomy: An Up-to-Date Systematic Review and Meta-Analysis. Journal of Obesity, 2018, 1–14. https://doi.org/10.1155/2018/3617458
- Somaschini, A., Cornara, S., Ferlini, M., Crimi, G., Camporotondo, R., Gnecchi, M., Ferrario Ormezzano, M., Oltrona Visconti, L., De Ferrari, G. M., & De Servi, S. (2019). Favorable effect of glycoprotein IIbIIIa inhibitors among STEMI patients treated with primary PCI and incomplete ST resolution. Platelets, 31(1), 48–54. https://doi.org/10.1080/09537104.2018.1562171
- Tavenier, A. H., Hermanides, R. S., Fabris, E., Lapostolle, F., Silvain, J., ten Berg, J. M., Lassen, J. F., Bolognese, L., Cantor, W. J., Cequier, N., Chettibi, M., Goodman, S. G., Hammett, C. J., Huber, K., Janzon, M., Merkely, B., Storey, R. F., Zeymer, U., Ecollan, P., . . . van ’t Hof, A. W. J. (2019). Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. Thrombosis and Haemostasis, 120(01), 065– 074. https://doi.org/10.1055/s-0039-1700546
- Verdoia, M., Kedhi, E., Suryapranata, H., & De Luca, G. (2019). Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials. Atherosclerosis, 284, 136–147. https://doi.org/10.1016/j.atherosclerosis.2019.02.011
- Vlachojannis, G. J., Vogel, R. F., Wilschut, J. M., Lemmert, M. E., Delewi, R., Diletti, R., van Vliet, R., van der Waarden, N., Nuis, R. J., Paradies, V., Alexopoulos, D., Zijlstra, F., Montalescot, G., Angiolillo, D. J., Krucoff, M. W., Van Mieghem, N. M., & Smits, P. C. (2020). COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. American Heart Journal, https://doi.org/10.1016/j.ahj.2020.03.005
- Wang, C., Xia, Q., Hu, B., Jiang, W., & Zhang, H. (2022). The Effectiveness and Safety of Huangqi Xixin Decoction for Cough Variant Asthma: A Systematic Review and Meta- Analysis. Evidence-Based Complementary and Alternative Medicine, 2022, 1–12. https://doi.org/10.1155/2022/9492100
- Wang, J. (n.d). From the Clinic for Cardiology of University of Lü beck Director: Prof. Dr. med. Ingo Eitel.
Cite this article
-
APA : Rahman, Z. u., Khan, I. A., & Amin, Q. N. U. (2022). Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials. Global Drug Design & Development Review, VII(II), 42-51. https://doi.org/10.31703/gdddr.2022(VII-II).06
-
CHICAGO : Rahman, Zia ur, Irfan Ali Khan, and Qazi Najeeb Ullah Amin. 2022. "Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials." Global Drug Design & Development Review, VII (II): 42-51 doi: 10.31703/gdddr.2022(VII-II).06
-
HARVARD : RAHMAN, Z. U., KHAN, I. A. & AMIN, Q. N. U. 2022. Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials. Global Drug Design & Development Review, VII, 42-51.
-
MHRA : Rahman, Zia ur, Irfan Ali Khan, and Qazi Najeeb Ullah Amin. 2022. "Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials." Global Drug Design & Development Review, VII: 42-51
-
MLA : Rahman, Zia ur, Irfan Ali Khan, and Qazi Najeeb Ullah Amin. "Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials." Global Drug Design & Development Review, VII.II (2022): 42-51 Print.
-
OXFORD : Rahman, Zia ur, Khan, Irfan Ali, and Amin, Qazi Najeeb Ullah (2022), "Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials", Global Drug Design & Development Review, VII (II), 42-51
-
TURABIAN : Rahman, Zia ur, Irfan Ali Khan, and Qazi Najeeb Ullah Amin. "Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials." Global Drug Design & Development Review VII, no. II (2022): 42-51. https://doi.org/10.31703/gdddr.2022(VII-II).06